Georgia’s coronavirus numbers made reopening look safe. But they were a lie (via latimesopinion)
“I have a hard time understanding how this happens without it being deliberate,” microbiology and molecular genetics PhD and state Rep. Jasmine Clark told the Journal Constitution. “Literally nowhere ever in any type of statistics would that be acceptable.”
Georgia isn’t the only state itching to reopen that has a penchant for dubious data. Florida actively tried suppressing county coroners from releasing COVID-19Time will tell if Georgians will pay the price for the irresponsibility and incompetence of their leaders, or if they’ll catch a break. Hot, humid summer weather could send coronavirus into a remission unearned by responsible public health strategies.One thing, however, is certain: Wishful thinking isn’t going to end this pandemic.
Stay home if you can, wear a mask, and don’t let politically motivated talk of reopening lull you into a false sense of security.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
19 Times The Internet Hilariously Dragged 'Harry Potter''[19 years later] Hermione: it's coronaVIRus not coronavirUS.'
Read more »
Coronavirus live updates: 'Positive' vaccine data lifts Moderna stock; Spain's GDP could fall more than 9.5%Covid-19 has now infected more than 4.7 million people around the world as of Monday, killing at least 315,496 people.
Read more »
Moderna's stock soars on positive early-stage data for its coronavirus vaccine candidateShares of Moderna Inc. jumped 25.1% in premarket trading on Monday after the biotechnology company announced positive results from a Phase 1 clinical trial for its experimental mRNA coronavirus vaccine. The trial was done in partnership with the National Institute of Allergy and Infectious Diseases. Within 43 days and after two doses, the participants taking one of two dosing levels of the vaccine candidate reported the same or higher level of antibodies as in blood samples gathered by patients who have recovered from COVID-19, the company said. There were four adverse events during the trial, including one participant who reported a severe skin reaction where the investigational vaccine was administered. "These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25" micrograms, Moderna chief medical officer Dr. Tal Zaks said in a news release. The next step is a Phase 2 trial, which has been approved to move forward by the Food and Drug Administration. It will focus on two dosing levels (50 microgram and 100 microgram). The early-stage trial had a third dosing level, 250 micrograms. Moderna's vaccine candidate is widely viewed as a frontrunner in the effort to develop the first vaccine for the virus. The preclinical company said earlier this month that the Phase 2 trial will begin "shortly," and on Monday it said it expects a Phase 3 trial to begin in July, if the vaccine is successful in the mid-stage trial. Moderna's stock has soared 240.9% year-to-date. The S&P 500 , in comparison, is down 11.3%.
Read more »
COVID-19 case tally: 4.73 million cases, 315,482 fatalities and Brazil passes Spain and Italy by case numberThe global case tally for the coronavirus that causes COVID-19 climbed to 4.73 million on Monday, according to data aggregated by Johns Hopkins University....
Read more »
Coronavirus infection rate in L.A. County is falling. But it's still in the danger zoneLast week, L.A. County officials released data that showed coronavirus infection rate had fallen. But it needs to continue falling to avoid danger.
Read more »
Global dividends forecast to fall as much as 35% in 2020: Janus HendersonDividends paid to shareholders could fall by as much as 35% in 2020, as the coronavirus pandemic cuts companies' profits, data from asset manager Janus Henderson showed on Monday.
Read more »